Positive interim results in P2 trial of proprietary adult stem cells Read more…
New FDA approved Facility will support Product Delineation Strategies Read more…
Net loss before tax of $27.8 M for the half-year, compared with $17.6 M for the previous corresponding period Read more…
New Granted Claims Confer Exclusive, Long-Term Commercial Rights Read more…
Clinical trial of Mesenchymal Precursor Cells in patients With RA Read more…
Results support progression of clinicals to P3 Read more…
MSB.AX’s off-the-shelf, allogeneic, Mesenchymal Precursor Cell (MPC) product for Type 2 diabetes … Read more…
Receives Singapore Health Sciences Authority (HSA) regulatory clearance to begin P2 trial Read more…
ASX: MSB received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center P2 clinical trial Read more…
P2 Stem Cell Trial for Lumbar Disc Repair Read more…
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.